Effect of PARACT (PARAmedical Interventions on Patient ACTivation) on the Cancer Care Pathway: Protocol for Implementation of the Patient Activation Measure-13 Item (PAM-13) Version
December 9, 2020

Effect of PARACT (PARAmedical Interventions on Patient ACTivation) on the Cancer Care Pathway: Protocol for Implementation of the Patient Activation Measure-13 Item (PAM-13) Version

By Matsuoka
Background: The rise within the variety of most cancers circumstances and the evolution of most cancers care administration have turn out to be a big downside for the French well being care system, thereby making affected person empowerment as a protracted sought-after purpose in continual pathologies. The implementation of an activation measure through the Affected person Activation Measure-13 merchandise (PAM-13) in the midst of most cancers care can probably spotlight the affected person’s wants, with nursing care adapting accordingly.
Goal: The goals of this PARACT (PARAmedical Interventions on Affected person ACTivation) multicentric research have been as follows: (1) consider the implementation of PAM-13 in oncology nursing practices in 5 complete most cancers facilities, (2) determine the obstacles and facilitators to the implementation of PAM-13, and (3) produce suggestions for the dissemination of such interventions in different complete most cancers facilities.
Strategies: This research will comply with the “Attain, Effectiveness, Adoption, Implementation, and Upkeep” framework and can consist of three phases. First, a strong preimplementation evaluation will probably be performed utilizing the Theoretical Domains Framework (TDF) linked to the “Functionality, Alternative, Motivation, and Conduct” mannequin to determine the obstacles and facilitators to implementing new nursing practices in every context. Then, utilizing the Conduct Change Wheel, we are going to personalize a technique for implementing the PAM-13, relying on the specificities of every context, to encourage acceptability by the nursing employees concerned within the mission. This evaluation will probably be carried out through a qualitative research by way of semistructured interviews.
Second, the affected person will probably be included within the research for 12 months, throughout which the affected person care pathway will probably be studied, significantly to gather all related contacts of oncology nurses and different well being professionals concerned within the pathway. The axes of nursing care may even be collected. The first purpose is to implement PAM-13. Secondary elements to be measured are the affected person’s nervousness stage, high quality of life, and well being literacy stage. The oncology nurses will probably be liable for finishing the questionnaires when the affected person is on the hospital for his/her intravenous chemotherapy/immunotherapy remedy. The questionnaires will probably be accomplished thrice in a 12 months: (1) on the time of the affected person’s enrollment, (2) at 6 months, and (3) at 12 months. Third, a postimplementation evaluation will probably be carried out by way of semistructured interviews utilizing the TDF to research the implementation issues at every website.
Outcomes: This research was supported by a grant from the French Ministry of Well being (PHRIP PARACT 2016-0405) and the Lucien Neuwirth Institute of Cancerology of Saint-Etienne, France. Knowledge assortment for this research is ongoing.
Conclusions: This research would enhance the carried out focused nursing interventions in most cancers facilities so {that a} affected person is obtainable a customized most cancers care pathway. Moreover, measuring the extent of activation and the implementation of measures meant to extend such activation may represent a big benefit in decreasing social well being inequalities.

Navigating uncharted waters: Creating a standardized method for evaluating and implementing biosimilar merchandise at a complete most cancers middle

Goal: The processes for formulary implementation and digital well being file (EHR) integration of biosimilar merchandise at a complete most cancers middle are described. Implications for analysis protocols are additionally mentioned.
Abstract: The present literature focuses on sensible concerns for formulary addition of biosimilar merchandise, however there’s a lack of steering on how you can implement the change, significantly throughout the EHR. Earlier than constructing the ordering instruments for biosimilars, the scientific and informatics groups ought to decide the function of biosimilars on the establishment, determine drug-specific product traits that have an effect on treatment construct, and characterize implications of future formulary adjustments or drug shortages. Leveraging an orderable file supplies the power to incorporate logic that maps to a number of merchandise and in addition permits for future implementation of adjustments throughout the treatment file fairly than requiring “swaps” on the remedy protocol stage. The institutional overview board ought to coordinate adjustments in affected analysis protocols and consent kinds and work with principal investigators to amend protocols when obligatory. Pharmacy leaders ought to develop processes to supervise stock in the course of the transition interval and decrease the chance of errors.
Conclusion: The event of a standardized method for evaluating and implementing biosimilar merchandise improves effectivity and collaboration among the many numerous group members liable for the merchandise’ integration into present workflows, together with implications for scientific analysis. Implementing biosimilars for brokers used to deal with most cancers will pose new challenges and require extra concerns. Partial implementation of biosimilars continues to pose a number of challenges within the provision of affected person care.
Effect of PARACT (PARAmedical Interventions on Patient ACTivation) on the Cancer Care Pathway: Protocol for Implementation of the Patient Activation Measure-13 Item (PAM-13) Version

Effect of PARACT (PARAmedical Interventions on Patient ACTivation) on the Cancer Care Pathway: Protocol for Implementation of the Patient Activation Measure-13 Item (PAM-13) Version

Matrix stiffness epigenetically regulates the oncogenic activation of the Sure-associated protein in gastric most cancers

In lots of cancers, tumour development is related to elevated tissue stiffness. But, the mechanisms associating tissue stiffness with tumorigenesis and malignant transformation are unclear. Right here we present that in gastric most cancers cells, the stiffness of the extracellular matrix reversibly regulates the DNA methylation of the promoter area of the mechanosensitive Sure-associated protein (YAP). Reciprocal interactions between YAP and the DNA methylation inhibitors GRHL2, TET2 and KMT2A may cause hypomethylation of the YAP promoter and stiffness-induced oncogenic activation of YAP.

Cancer Antigen 15-3 (CA 15-3) Breast Tumor Standard Grade

GWB-F0C8B0 25000 Unit Ask for price

Cancer Antigen 125 (CA 125) Standard Grade

GWB-565817 25000 Unit Ask for price

Cancer Antigen 125 (CA 125) Standard Grade

GWB-A9985A 50000 Unit Ask for price

Cancer Antigen 72-4 (CA 72-4) Standard Grade

GWB-626B6B 10 KU Ask for price

Cancer Antigen 72-4 (CA 72-4) Standard Grade

GWB-254330 50000 Unit Ask for price

Cancer Antigen 19-9 (CA 19-9) Standard Grade

GWB-1CA918 50000 Unit Ask for price

Cancer Antigen 19-9 (CA 19-9) Standard Grade

GWB-EECE0C 50000 Unit Ask for price

Human Breast Tumor Cancer Cells

ABC-HP013X 1 vial Ask for price
Description: Human breast cancer cells are isolated from human invasive ductal breast carcinoma sample. Human breast cancer cells are positive for pan-Cytokeratin, MGB-1 and MUC-1. CD90 staining shows that cultures are free of fibroblasts in 99%.

Cancer Antigen 15-3 (CA 15-3) Low Cross Grade

GWB-E47BC0 10000 Unit Ask for price

Breast Tumor Antigen

30C-CP1096B 50 KU
EUR 733
Description: Partially Purified Native Breast Tumor Antigen

Human Cancer PrimaCell4: Breast Tumor Cells

2-96027 1 Kit Ask for price

Breast tumor antigen (CA-15-3) Antibody, Concentrate

MAB521C 0.2ml
EUR 455

Cancer Antigen 15-3 (CA 15-3) Cell Culture Low Cross Grade

GWB-553B7B 10000 Unit Ask for price

Human Cancer Antigen CA15-3 Antigen Grade

GWB-C54ECC 50000 Unit Ask for price

Breast Cancer Antigen CA15-3 Enzyme Immunoassay Test Kit

GWB-150A4D ELISA_Kits Ask for price

Breast tumor antigen (CA-15-3) Antibody, Ready-To-Use

MAB521P 5ml
EUR 445

Human Cancer PrimaCell4: Breast Tumor Cells Growth Medium

9-46027 5 x 100 ml Ask for price

Standard grade - 601, Dia/Size in cm 15

6010-1500-100C 1 unit
EUR 16.27
Description: Standard grade - 601, Dia/Size in cm 15

Standard grade - 610, Dia/Size in cm 15

6100-1500-100C 1 unit
EUR 32.68
Description: Standard grade - 610, Dia/Size in cm 15

Standard grade - 961, Dia/Size in cm 15

9610-1500-100C 1 unit
EUR 44.54
Description: Standard grade - 961, Dia/Size in cm 15

Breast cancer and normal tissue array with stage and grade info

BR8012 each
EUR 306
Description: Breast cancer and normal tissue array with stage and grade info, 40 cases/80 cores, replaced by BR8014

Breast Cancer-Associated Antigen BRCAA1 (BRCAA1) Antibody

20-abx148333
  • Ask for price
  • Ask for price
  • 100 ug
  • 50 ug

Human Cancer Tissue Preparation Buffer 4: Breast Tumor Cells

9-80027 1 x 100 ml Ask for price

BSA (Standard Grade)

30-AB70 1 kg
EUR 875
Description: Standard Grade Bovine Serum Albumin (99% pure)

Human tumor marker CA549 for breast cancer ELISA Kit

SL3271Hu 96 Tests
EUR 468

Standard grade - 54, Dia/Size in cm 15 R

0540-1500-100C 1 unit
EUR 57.8
Description: Standard grade - 54, Dia/Size in cm 15 R

Standard grade - 55, Dia/Size in cm 15 R

0550-1500-100C 1 unit
EUR 69.48
Description: Standard grade - 55, Dia/Size in cm 15 R

Standard grade - 74, Dia/Size in cm 15 R

0740-1500-100C 1 unit
EUR 54.94
Description: Standard grade - 74, Dia/Size in cm 15 R

Breast fibroadenoma, breast tissue and breast cancer array, including pathology grade, TNM and clinical stage, 71 cases/80 cores

BR8010 row: 8; column: 10; cores: 80; cases: 71
EUR 306
Description: Breast fibroadenoma, breast tissue and breast carcinoma microarray, containing 7 cases of normal breast, 3 adjacent normal breast tissue, 20 fibroadenoma, 10 invasive lobular carcinoma, 30 invasive ductal carcinoma and 10 matched or matched lymph node metastatic carcinoma, single core per block

Gastrointestinal Cancer Antigen (CA 19-9), antigen grade

CA1991-N-10 10 KU
EUR 634.8

(untagged)-Human breast cancer antigen NY-BR-1.1 mRNA, partial cds

SC315066 10 µg Ask for price

Cancer Antigen 125 (CA 125) Low Cross Grade

GWB-87F2DB 10000 Unit Ask for price

Cancer Antigen CA50, Calibrator Grade Protein

GWB-T00050 50KU Ask for price

OPMA04167-50KIU - Human Cancer Antigen CA15-3 Antigen Grade Protein

OPMA04167-50KIU 50KU
EUR 2999

Breast Cancer and 8 types of tumor (middle advanced stage)tissue array

BR20838a each
EUR 474
Description: Breast Cancer and 8 types of tumor (middle advanced stage)tissue array, including pathology grade, TNM/stage with IHC Her-2 results, 118 cases/208 cores (core size 1.5mm), replacing BR20838

Tryptase Human Standard Grade

GWB-4CE407 0.1 mg Ask for price

Breast cancer with matched breast tissue array, including pathology grade, TNM and clinical stage, 12 cases/24 cores

FMG252 row: 4; column: 6; cores: 24; cases: 12
EUR 78
Description: Breast carcinoma with matched breast tissue microarray, containing 12 cases breast carcinoma with matched cancer adjacent breast tissue, duplicate cores per case

Breast cancer with breast tissue array, including pathology grade, TNM and clinical satge, 31 cases/50 cores

BRE502 row: 6; column: 9; cores: 50; cases: 31
EUR 162
Description: Breast carcinoma with breast tissue microarray, containing 16 cases of invasive carcinoma of no special type, 1 invasive lobular carcinoma, 3 medullary carcinoma, 4 invasive carcinoma, 1 metaplastic carcinoma, plus 25 adjacent normal or cancer adjacent breast tissue (19 matched with cancer), single core per block

Cancer Antigen CA242 (Gastrointestinal Cancer) Calibrator Grade Protein

GWB-T00229 50KU Ask for price

Breast cancer tissue array (pathology grade:1,2,3), including pathology grade, TNM and clinical stage, 45 cases/90 cores

BR901 row: 9; column: 10; cores: 90; cases: 45
EUR 270
Description: Breast invasive carcinoma of no special type tissue microarray, containing 40 cases of invasive carcinoma of no special type, 5 adjacent normal breast tissue, duplicate core per case

Breast cancer tissue array, with adjacent normal tissue and cancer adjacent breast tissue, including pathology grade,TNM and clinical stage, 45 cases/63 cores

FMG631 row: 7; column: 9; cores: 63; cases: 45
EUR 270
Description: Breast invasive carcinoma of no special type tissue microarray, containing 21 cases of invasive carcinoma of no special type, with adjacent normal and cancer adjacent breast tissue (18 matched with cancer), single core per block

Transferrin Receptor Standard Grade

GWB-CDE6A4 1 mg Ask for price

Cancer Antigen 27-29 (CA 27-29) Low Cross Grade

GWB-16367E 10000 Unit Ask for price

Florisil@ -200 Mesh Standard Grade

F01454 100G
EUR 229.1

Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 75 cases/150 cores, replacing BR1504b

BR1504c row: 10; column: 15; cores: 150; cases: 75
EUR 306
Description: Breast carcinoma with breast tissue microarray, containing 70 cases of invasive ductal carcinoma, 4 adjacent normal breast tissue and 1 breast tissue, duplicate cores per case (duplicated cores from the same patient were put onto upper and lower rows in the same position)

Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 188 cases/208 cores, replacing BR2085b

BR2085c row: 13; column: 16; cores: 208; cases: 188
EUR 546
Description: Breast carcinoma with breast tissue microarray, containing 144 cases of invasive carcinoma of no special type, 24 invasive lobular carcinoma, 1 breast tissue, 19 adjacent normal breast tissue, single core per case of carcinoma, duplicate cores per case of breast tissue and adjacent normal breast tissue

Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing T087c

FBR087d row: 3; column: 8; cores: 24; cases: 6
EUR 66
Description: Breast carcinoma with breast tissue microarray, containing 3 cases of invasive carcinoma of no special type, 1 invasive lobular carcinoma, 2 breast tissue, quadruple cores per case, 2 serial sections, divided into two identical 12 core arrays for testing different antibody dilutions

Breast Tumor Tissue Array - 16 cases of breast cancer, each in duplicates, paired with adjacent normal tissues

Z7020007 5 slides
EUR 1657.2
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Circulating tumor cell breast cancer detection kit (anti-HER-2 Ab Magbeads)

E601CM003 20 tests
EUR 2500

Standard grade - 610, Dia/Size in cm12.5

6100-1250-100C 1 unit
EUR 20.85
Description: Standard grade - 610, Dia/Size in cm12.5

Standard grade - 961, Dia/Size in cm12.5

9610-1250-50C 1 unit
EUR 14.2
Description: Standard grade - 961, Dia/Size in cm12.5

Standard grade - 961, Dia/Size in 46x57

9610-4657-100S 1 unit
EUR 424.61
Description: Standard grade - 961, Dia/Size in 46x57

Breast cancer

BR1008b each
EUR 306
Description: Breast cancer, lymph node metastatic carcinoma and adjacent normal tissue array, including pathology grade, TNM, clinical stage, and ER/PR/Her2 result, 100 cases/100 cores, replacing BR1008a

Breast cancer

BR724 each
EUR 270
Description: Breast cancer, adjacent and adjacent normal tissue array, 66 cases/72 cores

Breast cancer

BR725 each
EUR 270
Description: Breast cancer, adjacent and adjacent normal tissue array, 68 cases/72 cores

Cancer Antigen 125 (CA 125) High Purity Low Cross Grade

GWB-12E060 20000 Unit Ask for price

Cancer Antigen 125 (CA 125) Cell Culture Low Cross Grade

GWB-143910 25000 Unit Ask for price

Breast cancer with matched breast tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing BR251c

BR251d row: 3; column: 8; cores: 24; cases: 6
EUR 48
Description: Breast carcinoma with matched breast tissue microarray, containing 6 cases invasive carcinoma of no special type and matched cancer adjacent or adjacent normal breast tissue, quadruple cores per case

Breast cancer and breast tissue array, with metastatic carcinoma, including pathology grade, TNM and clinical stage, 96 cases/100 cores

FMG1001 row: 10; column: 10; cores: 100; cases: 96
EUR 258
Description: Breast cancer and breast tissue microarray, contaning 44 cases of invasive carcinoma of no special type, 5 medullary carcinoma, 1 neuroendocrine carcinoma, 37 metastatic invasive carcinoma of no special type, 2 metastatic lobular carcinoma, 1 metastatic medullary carcinoma, 3 breast tissue, 7 adjacent normal breast tissue, single core per block

Breast cancer tissue array with adjacent normal breast tissue, including pathology grade, TNM and clinical stage, 75 cases/150 cores

FMG1504 row: 10; column: 15; cores: 150; cases: 75
EUR 306
Description: Breast carcinoma tissue microarray with adjacent normal breast tissue, containing 70 cases of invasive carcinoma of no special type, 5 cases of adjacent normal breast tissue, duplicate cores per case (duplicated cores from the same patient were put onto upper and lower rows in the same position)

Breast cancer with matched breast tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing BR251b

FMG251c row: 3; column: 8; cores: 24; cases: 6
EUR 48
Description: Breast carcinoma with matched breast tissue microarray, containing 6 cases invasive carcinoma of no special type and matched cancer adjacent or adjacent normal breast tissue, quadruple cores per case

Breast cancer with cancer adjacent breast tissue array

BC081116e each
EUR 306
Description: Breast cancer with cancer adjacent breast tissue array, including invasive carcinoma of no special type, breast carcinoma with apocrine differentiation and AT tissue,pat hology grade, IHC (ER/PR/Her-2/Ki67) info, TNM/Stage (AJCC 7th edition), 107 cases/110 cores (core size 1.5mm), replacing BC081116d

Breast cancer tissue array, including pathology grade, TNM and clinical stage, 54 cases/108 cores

BR1081 row: 11; column: 10; cores: 108; cases: 54
EUR 306
Description: Breast carcinoma tissue microarray, containing 52 cases of invasive carcinoma of no special type, 1 each of carcinoid and medullary carcinomag, duplicate core per case

Breast cancer tissue array, including pathology grade, TNM and clinical stage, 64 cases/ 64 cores

BR641 row: 8; column: 8; cores: 64; cases: 64
EUR 270
Description: Breast invasive carcinoma of no special type tissue microarray, containing 64 cases of invasive carcinoma of no special type, single core per case

Breast cancer tissue array, including pathology grade, TNM and clinical stage, 24 cases/72 cores

BR727 row: 8; column: 9; cores: 64; cases: 64
EUR 306
Description: Breast invasive carcinoma of no special type tissue microarray, containing 21 cases invasive carcinoma of no special type, 3 normal breast tissue, triplicate core per case

Breast cancer tissue array, including pathology grade, TNM and clinical stage, 114 cases/114 cores

FMG1141 row: 11; column: 11; cores: 114; cases: 114
EUR 354
Description: Breast carcinoma tissue microarray, containing 96 invasive carcinoma of no special type, 7 medullary carcinoma, 7 invasive lobular carcinoma, 3 apocrine carcinoma, 1 invasive micropapillary carcinoma, single cores per case

Breast cancer tissue array, including pathology grade, TNM and clinical stage, 75 cases/150 cores

FMG1503 row: 10; column: 15; cores: 150; cases: 75
EUR 354
Description: Breast invasive carcinoma of no special type tissue microarray, containing 3 cases of cancer adjacent tissue, 1 fibroadenoma, 3 phyllodes tumor, 1 carcinoma in situ, plus 60 invasive carcinoma of no special type, duplicate cores per case

Breast cancer tissue array, including pathology grade, TNM and clinical stage, 104 cases/208 cores

FMG2088 row: 13; column: 16; cores: 208; cases: 104
EUR 474
Description: Breast carcinoma tissue microarray, containing 97 cases of invasive carcinoma of no special type, 2 invasive lobular carcinoma, 3 medullary carcinoma,1 eachof apocrine carcinoma and mixed carcinoma, duplicate cores per case

Breast cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases/48 cores

FMG484 row: 6; column: 8; cores: 48; cases: 48
EUR 204
Description: Breat invasive carcinoma of no special type tissue microarray, containing 48 cases of invasive carcinoma of no special type, single core per case

Breast cancer tissue array, including pathology grade, TNM and clinical stage, 50 cases/ 50 cores

FMG501 row: 5; column: 10; cores: 50; cases: 50
EUR 270
Description: Breast invasive carcinoma of no special type tissue microarray, containing 50 cases of invasive carcinoma of no special type, single cores per case

Breast cancer tissue array, including pathology grade, TNM and clinical stage, 72 cases/72 cores

FMG721 row: 8; column: 9; cores: 72; cases: 72
EUR 270
Description: Breast carcinoma tissue microarray, containing 45 cases of invasive carcinoma of no special type, 3 lobular-ductal mixed carcinoma, 10 each of lobular carcinoma and medullary carcinoma, 4 metaplastic carcinoma, single core per case

Standard grade - 131, Dia/Size in cm 4.7

1310-0470-100C 1 unit
EUR 82.59
Description: Standard grade - 131, Dia/Size in cm 4.7

Standard grade - 161, Dia/Size in cm 4.7

1610-0470-100C 1 unit
EUR 88.63
Description: Standard grade - 161, Dia/Size in cm 4.7

Standard grade - 601, Dia/Size in cm 11

6010-1100-100C 1 unit
EUR 11.84
Description: Standard grade - 601, Dia/Size in cm 11

Standard grade - 601, Dia/Size in cm 12.

6010-1250-100C 1 unit
EUR 12.79
Description: Standard grade - 601, Dia/Size in cm 12.

Standard grade - 601, Dia/Size in cm 46

6018-4657-100S 1 unit
EUR 197.06
Description: Standard grade - 601, Dia/Size in cm 46

Standard grade - 613, Dia/Size in cm 4.7

6130-0470-100C 1 unit
EUR 7.89
Description: Standard grade - 613, Dia/Size in cm 4.7

Standard grade - 613, Dia/Size in cm 7.5

6130-0750-100C 1 unit
EUR 8.69
Description: Standard grade - 613, Dia/Size in cm 7.5

Standard grade - 613, Dia/Size in cm 11

6130-1100-100C 1 unit
EUR 11.53
Description: Standard grade - 613, Dia/Size in cm 11

Standard grade - 613, Dia/Size in cm 50

6130-5050-100S 1 unit
EUR 169.94
Description: Standard grade - 613, Dia/Size in cm 50

Standard grade - 615, Dia/Size in cm 12.

6150-1250-100C 1 unit
EUR 18.27
Description: Standard grade - 615, Dia/Size in cm 12.

Standard grade - 615, Dia/Size in cm 18.

6150-1850-100C 1 unit
EUR 33.29
Description: Standard grade - 615, Dia/Size in cm 18.

Standard grade - 615, Dia/Size in cm 46

6150-4657-100S 1 unit
EUR 197.98
Description: Standard grade - 615, Dia/Size in cm 46

Standard Grade -631 , Dia/size in cm 7

6310-0700-100C 1 unit
EUR 10.42
Description: Standard Grade -631 , Dia/size in cm 7

Standard Grade -631 , Dia/size in cm 9

6310-0900-100C 1 unit
EUR 11.84
Description: Standard Grade -631 , Dia/size in cm 9

Standard grade - 631, Dia/Size in cm 12.

6310-1250-100C 1 unit
EUR 17.84
Description: Standard grade - 631, Dia/Size in cm 12.

Standard Grade =642 , Dia/size in 7 cm

6420-0700-100C 1 unit
EUR 13.41
Description: Standard Grade =642 , Dia/size in 7 cm

Standard Grade =642 , Dia/size in 9 cm

6420-0900-100C 1 unit
EUR 13.41
Description: Standard Grade =642 , Dia/size in 9 cm

Standard Grade =642 , Dia/size in 11 cm

6420-1100-100C 1 unit
EUR 14.86
Description: Standard Grade =642 , Dia/size in 11 cm

Standard grade - 642, Dia/Size in cm 12.

6420-1250-100C 1 unit
EUR 16.27
Description: Standard grade - 642, Dia/Size in cm 12.

Standard grade - 642, Dia/Size in cm 46

6428-4657-100S 1 unit
EUR 954.89
Description: Standard grade - 642, Dia/Size in cm 46

Standard grade - 961, Dia/Size in cm 9

9610-0900-100C 1 unit
EUR 22.26
Description: Standard grade - 961, Dia/Size in cm 9

Standard grade - 961, Dia/Size in cm 11

9610-1100-100C 1 unit
EUR 26.7
Description: Standard grade - 961, Dia/Size in cm 11

Standard grade - 961, Dia/Size in cm 12.

9610-1250-100C 1 unit
EUR 32.68
Description: Standard grade - 961, Dia/Size in cm 12.

Proteinase K, Recombinant, Standard Grade

9250-100 each
EUR 124.8

Proteinase K, Recombinant, Standard Grade

9250-10G each
EUR 4627.2

Proteinase K, Recombinant, Standard Grade

9250-1G each
EUR 548.4

Proteinase K, Recombinant, Standard Grade

9250-500 each
EUR 314.4

Proteinase K, Recombinant, Standard Grade

9251-100 each
EUR 1266

Proteinase K, Recombinant, Standard Grade

9251-25 each
EUR 352.8

Proteinase K, Recombinant, Standard Grade

9251-5 each
EUR 144

Standard Grade-610, Dia/size in 7 cm

6100-0700-100C 1 unit
EUR 13.41
Description: Standard Grade-610, Dia/size in 7 cm

CancerSeq™ Paraffin Tissue Tumor Block: Breast

T2235086-SB 1 Block
EUR 4215

(untagged)-Human serologically defined breast cancer antigen NY-BR-96 mRNA, complete cds

SC313428 10 µg Ask for price

CancerSeq™ Paraffin Tissue Tumor Slides: Breast

T2235086-ST 5 Slides
EUR 601

Standard grade - 601, Dia/Size in cm 7 R

6010-0700-100C 1 unit
EUR 15.8
Description: Standard grade - 601, Dia/Size in cm 7 R

Standard grade - 601, Dia/Size in cm 9 R

6010-0900-100C 1 unit
EUR 10.42
Description: Standard grade - 601, Dia/Size in cm 9 R

Standard grade - 613, Dia/Size in cm 7 R

6130-0700-100C 1 unit
EUR 8.69
Description: Standard grade - 613, Dia/Size in cm 7 R

Standard grade - 613, Dia/Size in cm 9 R

6130-0900-100C 1 unit
EUR 9.79
Description: Standard grade - 613, Dia/Size in cm 9 R

Breast cancer tissue array with normal breast tissue, including pathology grade, TNM, clinical stage and Her-2 results, 5 cases/5 cores

BRC051 row: 1; column: 5; cores: 5; cases: 5
EUR 42
Description: Breast invasive carcinoma of no special type microarray, containing 4 casee of breast invasive carcinoma of no special type and 1 normal breast tissue, single core per case

Standard grade - 54, Dia/Size in cm 12.5

0540-1250-100C 1 unit
EUR 44.54
Description: Standard grade - 54, Dia/Size in cm 12.5

Standard grade - 54, Dia/Size in cm 18.5

0540-1850-100C 1 unit
EUR 101.67
Description: Standard grade - 54, Dia/Size in cm 18.5

Standard grade - 55, Dia/Size in cm 11

0550-1100-100C 1 unit
EUR 38.04
Description: Standard grade - 55, Dia/Size in cm 11

Standard grade - 55, Dia/Size in cm 12.5

0550-1250-100C 1 unit
EUR 48.17
Description: Standard grade - 55, Dia/Size in cm 12.5

Standard grade - 74, Dia/Size in cm 12.5

0740-1250-100C 1 unit
EUR 41.54
Description: Standard grade - 74, Dia/Size in cm 12.5

Standard grade - 94, Dia/Size in cm 7

0940-0700-100C 1 unit
EUR 22.26
Description: Standard grade - 94, Dia/Size in cm 7

Standard grade - 94, Dia/Size in cm 12.5

0940-1250-100C 1 unit
EUR 41.54
Description: Standard grade - 94, Dia/Size in cm 12.5

Breast Tumor Tissue Array - duplicated 70 cases covering all the common types of breast cancer and 5 cases of normal and

Z7020004 5 slides
EUR 1422

Breast Tumor Tissue Array - Duplicated 70 cases covering all the common types of breast cancer and 5 cases of normal and

Z7020005 5 slides
EUR 1422

Breast Tumor Tissue Array - Duplicated 36 cases covering all the common types of breast cancer and 12 cases of normal an

Z7020008 5 slides
EUR 1657.2
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Breast Tumor Tissue Array - Duplicated 36 cases covering all the common types of breast cancer and 12 cases of normal an

Z7020009 5 slides
EUR 1657.2
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Human Cancer PrimaCell4: Breast Tumor Cells Growth Supplements with Serum (for 500 ml medium)

9-47027 1 Set Ask for price

Cancer Antigen 19-9 (CA 19-9) High Purity Iodination Grade

GWB-453206 50000 Unit Ask for price

Breast cancer with matched cancer adjacent breast tissue array

BR804b each
EUR 306
Description: Breast cancer with matched cancer adjacent breast tissue array, including pathology grade, TNM, clinical stage and IHC markers (ER, PR, Her-2 and Ki67), 40 cases/80 cores, replacing BR804a

Standard grade - 54, Dia/Size in cm 46x5

0540-4657-100S 1 unit
EUR 525.21
Description: Standard grade - 54, Dia/Size in cm 46x5

Standard grade - 55, Dia/Size in cm 46x5

0550-4657-100S 1 unit
EUR 819.06
Description: Standard grade - 55, Dia/Size in cm 46x5

Standard grade - 74, Dia/Size in cm 46x5

0740-4657-100S 1 unit
EUR 556.3
Description: Standard grade - 74, Dia/Size in cm 46x5

Standard grade - 94, Dia/Size in cm 46x5

0940-4657-100S 1 unit
EUR 531.04
Description: Standard grade - 94, Dia/Size in cm 46x5

Filamin Standard Grade From Chicken Gizzard

GWB-955E5F 0.25 mg Ask for price

Breast cancer TMA

BR602 each
EUR 270
Description: Breast cancer TMA, 3 samples have matched cancer adjacent tissue samples, including pathology grade, TNM and clinical stage (reference AJCC 8th version), 57 cases/60 cores (Core Size 1.5mm), recent tear collections

Breast cancer with adjacent normal breast tissue array, including pathology grade, TNM and clinical stage, 72 cases/72 cores, replacing FMG08013e

FMG08013f row: 8; column: 9; cores: 72; cases: 72
EUR 168
Description: Breast carcinoma with adjacent normal breast tissue microarray, containing 63 cases of invasive carcinoma of no special type, 6 medullary carcinoma, 3 adjacent normal breast tissue, single core per case

Breast cancer survey tissue array (5 of 5), including TNM, clinical stage and pathology grade, 208 cases/208 cores

BR20836 row: 13; column: 16; cores: 208; cases: 208
EUR 474
Description: Breast carcinoma tissue microarray (slide 5 of 1040 cases of breast cancer survey slide set), containing 207 cases of invasive carcinoma of no special type, 1 mucinous adenocarcinoma, single core per case

Bovine Serum Albumin Standard Grade pH 7.0

GWB-555343 1 kg Ask for price

Bovine Serum Albumin Standard Grade pH 5.2

GWB-AA0E82 1 kg Ask for price

Bovine Serum Albumin, Standard Grade, pH 7.0

A0210-010 100g
EUR 170

Bovine Serum Albumin, Standard Grade, pH 7.0

A0210-050 500g
EUR 720

Bovine Serum Albumin, Standard Grade, pH 7.0

A0210-100 1Kg
EUR 890

Bovine Serum Albumin, Standard Grade, pH 7.0

A0210-110 10Kg
EUR 8100

Human AFP Antigen Standard

HPX994S 96 Tests
EUR 95

Human CRP Antigen Standard

HPX995S 96 Tests
EUR 100

Standard grade - 54, Dia/Size in cm 7 Re

0540-0700-100C 1 unit
EUR 22.26
Description: Standard grade - 54, Dia/Size in cm 7 Re

Standard grade - 54, Dia/Size in cm 9 Re

0540-0900-100C 1 unit
EUR 29.67
Description: Standard grade - 54, Dia/Size in cm 9 Re
Direct alteration of extracellular cues through in situ matrix softening reversed YAP exercise and the epigenetic program. Our findings recommend that epigenetic reprogramming of the mechanophysical properties of the extracellular microenvironment of stable tumours might symbolize a therapeutic technique for the inhibition of most cancers development.